JNJ-80202135, EFGARTIGIMOD ALFA clinical trials

Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab

This study compares two existing treatments, nipocalimab and efgartigimod, for a muscle weakness condition called generalised myasthenia gravis. It aims to see how well they work and if one is better than the other, especially when people switch from one drug to the other.